Journals / International Journal of Medical Biochemistry / 2020 / Cilt: 3 - Sayı: 2

Evaluation of analytical performance of two iPTH immunoassay methods in hemodialysis patients

Pages
56–61
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

For consistency, is suggested that patient follow-up should be performed using the same kits, the same analysis system, and in the same laboratory.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Renal excretion of parathormone (PTH) C-terminal fragments can cause an accumulation of the C-terminal form in the blood in chronic kidney disease patients.
📊
Key Findings & Data:This study was designed to compare the Architect iPTH test measured using the Architect i2000SR System (Abbott Laboratories, Lake Bluff, IL, USA) and the Beckman iPTH test measured using the Beckman Coulter Dxi 800 (Beckman Coulter, Brea, CA, USA), which are 2 immunoassay systems commonly used in routine laboratory analyses, and to evaluate the analytical performance in hemodialysis patients.Methods: The immunoassays were assessed for accuracy, precision, limit of blank (LoB), limit of detection (LoD), and limit of quantification (LoQ).Results: A total of 86 samples were run on both systems and the correlation between the methods was evaluated.
💡
Conclusion & Impact:For consistency, is suggested that patient follow-up should be performed using the same kits, the same analysis system, and in the same laboratory.
🔬Design:Research Article
📍Scope:86 samples
⚙️Variables:Domain Parameters

Özet

Objectives: Renal excretion of parathormone (PTH) C-terminal fragments can cause an accumulation of the C-terminal form in the blood in chronic kidney disease patients. Thus, the measurement of the active form of PTH has become important. This study was designed to compare the Architect iPTH test measured using the Architect i2000SR System (Abbott Laboratories, Lake Bluff, IL, USA) and the Beckman iPTH test measured using the Beckman Coulter Dxi 800 (Beckman Coulter, Brea, CA, USA), which are 2 immunoassay systems commonly used in routine laboratory analyses, and to evaluate the analytical performance in hemodialysis patients.Methods: The immunoassays were assessed for accuracy, precision, limit of blank (LoB), limit of detection (LoD), and limit of quantification (LoQ).Results: A total of 86 samples were run on both systems and the correlation between the methods was evaluated. The i2000SR and Dxi 800 assays demonstrated good performance in terms of precision, accuracy, LoB, LoD, and LoQ. Intra-class correlation coefficient analysis revealed a difference of 0.912 (0.489-0.968) with a y=2.58+1.53x equation.Conclusion: It was confirmed that these analyzers widely used for iPTH measurement operate at an acceptable level of analytical performance. It was observed that the measurements obtained from both analyzers were consistent, but the Abbott Architect i2000SR provided higher results than the Beckman Coulter Dxi800. For consistency, is suggested that patient follow-up should be performed using the same kits, the same analysis system, and in the same laboratory.

🔖

Cite This Article

YİS, Ö. M., BUGDAYCİ, G., PEHLİVAN, M. B., YÜCE, N., YILDIZ, R. N., BASOL, M. (2020). Evaluation of analytical performance of two iPTH immunoassay methods in hemodialysis patients. International Journal of Medical Biochemistry, Cilt: 3 - Sayı: 2, 56–61. https://ajindex.com/articles/270343

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Tregear GW, Van Rietschoten J, Greene E, Keutmann HT, Niall HD, Reit B, et al. Bovine parathyroid hormone: minimum chain length of synthetic peptide required for biological activity. Endocrinology 1973;93(6):1349–53
  2. Smit MA, van Kinschot CMJ, van der Linden J, van Noord C, Kos S. Clinical Guidelines and PTH Measurement: Does Assay Generation Matter?. Endocr Rev 2019;40(6):1468–80
  3. D'Amour P. Circulating PTH molecular forms: what we know and what we don't. Kidney Int Suppl 2006;(102):S29–S33
  4. Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKDMBD) Guideline Update: what's changed and why it matters. Kidney Int 2017;92(1):26–36
  5. Eddington H, Hudson JE, Oliver RL, Fraser WD, Hutchison AJ, Kalra PA. Variability in parathyroid hormone assays confounds clinical practice in chronic kidney disease patients. Ann Clin Biochem 2014;51(Pt 2):228–36
  6. Lepage R, Roy L, Brossard JH, Rousseau L, Dorais C, Lazure C, et al. A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 1998;44(4):805–9
  7. Tan K, Ong L, Sethi SK, Saw S. Comparison of the Elecsys PTH(1- 84) assay with four contemporary second generation intact PTH assays and association with other biomarkers in chronic kidney disease patients. Clin Biochem 2013;46(9):781–6
  8. Cavalier E, Delanaye P, Nyssen L, Souberbielle JC. Problems with the PTH assays. Ann Endocrinol (Paris) 2015;76(2):128– 33
  9. Hanon EA, Sturgeon CM, Lamb EJ. Sampling and storage conditions influencing the measurement of parathyroid hormone in blood samples: a systematic review. Clin Chem Lab Med 2013;51(10):1925–41
  10. Schleck ML, Souberbielle JC, Delanaye P, Plebani M, Cavalier E. Parathormone stability in hemodialyzed patients and healthy subjects: comparison on non-centrifuged EDTA and serum samples with second- and third-generation assays. Clin Chem Lab Med 2017;55(8):1152–9
  11. CLSI. Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline-Second Edition. CLSI document EP17-A2. Wayne; PA; USA. Clinical Laboratory Standards Institute. 2012. Available at: https://clsi.org/ media/1430/ep17a2_sample.pdf. Accessed Apr 7, 2020
  12. CLSI. Evaluation of precision of quantitative measurement procedures; approved guideline-third edition. CLSI document EP05-A3. Wayne;